Compare General Motors Company (GM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs TransMedics Group Inc — how do they compare? General Motors Company trades at $82.73 (market cap $72.17B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: General Motors Company is far larger — about 26.3× TransMedics Group Inc's market cap, and General Motors Company pays a 0.88% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and TransMedics Group Inc for 24 Days on average.
| GM | TMDX | |
|---|---|---|
Market Cap | $72.17B | $2.74B |
Volume | 4,900,304 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $150.42 |
52-Week Low | $55.35 | $61.99 |
Typical Hold Time | 83 Days | 24 Days |
Enterprise Value | $175.15B | $3.13B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 1.56% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong cash flow ($26.9B operating cash flow in 2025) but declining profit margins (1.05% net margin). Recent Q3 2026 sales declined 5.5% as EV demand weakens, though regulatory savings of $20.4B through 2031 provide some offset. Analyst consensus remains bullish with a $102.08 price target representing 24% upside potential.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but long-term value exists through cost savings initiatives and strong cash generation. The stock trades at attractive valuations (P/S 0.42x) with 67% analyst buy ratings, though competitive pressure from Asian automakers and EV transition challenges present significant execution risks for investors.
TMDX trades at $79.00, down 2.55% amid bearish technical signals. The stock shows strong profitability with 22.69% net margin and 36.28% ROE, though recent earnings misses and margin compression from 2025 to 2026 raise concerns. Analyst consensus remains bullish with a $99.75 price target, but multiple legal investigations into fiduciary duties create uncertainty. Revenue growth continues with 2026 guidance at $668M.
The stock presents a growth opportunity with analyst upside potential, but faces near-term headwinds from earnings volatility and legal scrutiny. Execution on 2026 guidance and resolution of governance concerns will be critical for sustained momentum. Current valuation at 20.47 P/E appears reasonable given growth prospects if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
